Trial Profile
Sifrol® (Pramipexole) Impact on RLS: A 12-weeks Observational Study in Patients With Primary RLS
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2014
Price :
$35
*
At a glance
- Drugs Pramipexole (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 03 Oct 2014 New trial record